ScholarIQanswers from OpenAlex & ORCID
Lainie P. Martin
ResearcherPublications, citations & collaboration network
Lainie P. Martin is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Lainie P. Martin have?
ScholarIQindexed works
Lainie P. Martin has 282 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Lainie P. Martin have?
ScholarIQcitation count
Lainie P. Martin has 7,640 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Lainie P. Martin?
ScholarIQh-index
Lainie P. Martin has an h-index of 41 in OpenAlex.
What is the i10-index of Lainie P. Martin?
ScholarIQi10-index
Lainie P. Martin has an i10-index of 75 in OpenAlex.
What is the ORCID of Lainie P. Martin?
ScholarIQorcid
The ORCID for Lainie P. Martin is on the source record.
What is the OpenAlex record for Lainie P. Martin?
ScholarIQopenalex
The OpenAlex for Lainie P. Martin is on the source record.
What are the most-cited papers on Lainie P. Martin?
ScholarIQmost cited works
Platinum Resistance: The Role of DNA Repair Pathways
Lainie P. Martin, Thomas C. Hamilton, Russell J. Schilder
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum‐Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela Cristea, Maria C. DeRosa, Eric Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel N. Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath, Joyce F. Liu, Haider Mahdi, Lainie P. Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, David M. O’Malley, Sanja Percac‐Lima, Elena Ratner, Steven W. Remmenga, Roberto Vargas, Theresa L. Werner, Emese Zsíros, Jennifer L. Burns, Anita M. Engh
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny, Yolanda García García, Susana Banerjee, Domenica Lorusso, Jung‐Yun Lee, John W. Moroney, Nicoletta Colombo, A. Roszak, Jacqueline M. Tromp, Tashanna Myers, Jeong‐Won Lee, Mario Beiner, Casey Cosgrove, David Cibula, Lainie P. Martin, Renaud Sabatier, Joseph Buscema, Purificación Estévez-García, Lan Coffman, Shibani Nicum, Linda Duska, Sandro Pignata, Fernando Gálvez, Yuemei Wang, Michael Method, Anna Berkenblit, Diana Bello Roufai, Toon Van Gorp
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Deborah K. Armstrong, Ronald D. Alvarez, Floor Backes, Jamie N. Bakkum‐Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Viola C. Chitiyo, Mihaela Cristea, Maria C. DeRosa, Eric Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel N. Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath, Gary S. Leiserowitz, Joyce F. Liu, Lainie P. Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, Sanja Percac‐Lima, Steven W. Remmenga, John O. Schorge, Daphne Stewart, Premal H. Thaker, Roberto Vargas, Andrea Wahner Hendrickson, Theresa L. Werner, Emese Zsíros, Mary A. Dwyer, Lisa E. Hang
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
John K. Chan, Mark F. Brady, Richard T. Penson, Helen Huang, Michael J. Birrer, Joan L. Walker, Paul DiSilvestro, Stephen C. Rubin, Lainie P. Martin, Susan A. Davidson, Warner K. Huh, David M. O’Malley, Matthew Boente, Helen Michael, Bradley J. Monk